Search

Search Constraints

You searched for: Author/Creator Sugawara, Shunichi

Search Results

1. A Phase II Study of Amrubicin as a Third‐Line or Fourth‐Line Chemotherapy for Patients With Non‐Small Cell Lung Cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0901. (26th February 2013)

2. A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A. (September 2016)

3. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Issue 10308 (9th October 2021)

4. Adjuvant atezolizumab in Japanese patients with resected stage IB‐IIIA non‐small cell lung cancer (IMpower010). Issue 12 (21st September 2022)

5. ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor‐naïve Japanese patients with EGFR mutation‐positive non‐small‐cell lung cancer. Issue 8 (29th June 2018)

6. Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti‐Programmed Cell Death 1 Monotherapy for Advanced Non‐Small Cell Lung Cancer. (7th November 2019)

7. Association of Immune‐Related Adverse Events with Clinical Benefit in Patients with Advanced Non‐Small‐Cell Lung Cancer Treated with Nivolumab. (22nd June 2018)

8. Association of immune‐related pneumonitis with clinical benefit of anti‐programmed cell death‐1 monotherapy in advanced non‐small cell lung cancer. (13th June 2021)

9. Bevacizumab beyond disease progression after first‐line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non–small cell lung cancer (West Japan Oncology Group 5910L): An open‐label, randomized, phase 2 trial. Issue 7 (1st February 2016)

10. Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial. Issue 1 (January 2022)